Form 4: Bicara Therapeutics Director Receives Stock Option Grant

Director Michael Powell was granted 19,475 stock options in Bicara Therapeutics Inc. as part of standard equity compensation.

Summary

• Director Michael Powell received a grant of 19,475 stock options on June 9, 2026.
• The options have an exercise price of $20.56 per share.
• The options are set to expire on June 9, 2036.
• Vesting occurs on the earlier of June 9, 2027, or the date of the next Annual Meeting of Stockholders, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is subject to market volatility and the future performance of the company's common stock.

Future Outlook

The options vest in one year, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain experienced leadership for oversight.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 9, 2027, or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Bicara Therapeutics, BCAX, Form 4, Insider Trading, Stock Options, Director Compensation